Navigation Links
Exergen Granted New Patent for Temporal Artery Thermometers

WATERTOWN, Mass., March 17, 2011 /PRNewswire/ -- A recently issued patent extends protection of the technology incorporated in Exergen's award winning and best selling medical thermometer brand, the TemporalScanner™ Temporal Artery Thermometers.  Exergen Corporation has recently been granted U.S. Patent No. 7,787,938, entitled, "Temporal Artery Temperature Detector" by the US Patent and Trademark Office, adding to the already extensive Exergen portfolio of valuable intellectual property rights that it has developed for its non-invasive thermometry products.

With 15 US Patents protecting the TemporalScanner professional versions, and 10 US Patents protecting the home model, Exergen continues to vigorously defend its intellectual property rights.  It has brought a number of lawsuits over the years to successfully stop companies from infringing upon Exergen's rights with regard to infrared temperature measuring products. Currently Exergen has brought suit against Kidz-Med, Inc., American Scientific Resources, Inc. and Tecnimed S.R.L for patent infringement in the United States District Court for the District of Massachusetts.

"This new patent confirms and protects important innovations in non-invasive thermometry contained in our Temporal Artery Thermometers," said Dr. Francesco Pompei, Exergen CEO and inventor of the patented technology.  "These innovations are central to the overwhelming success of the temporal artery method, which many competitors would like to use.  As a U.S. manufacturer we rely on strong patent protection to protect our rights, and do our part to help protect the spirit of innovation in a highly competitive world."

Exergen Corporation is recognized worldwide as an innovator and leading manufacturer of patented infrared thermometers, scanners, sensors and controls.  Its products are used in a wide variety of industrial and medical applications for both professionals and consumers.  Its TemporalScanner medical thermometers are responsible for nearly a billion temperatures taken per year in thousands of hospitals and clinics.  Its home model is used in more than 3 million homes and is the #1 selling retail brand. For additional information, visit

SOURCE Exergen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Exergen TemporalScanner Effective in Detecting Fevers in Children Aged 1-4 Years, Study Finds
2. Exergen TemporalScanner Thermometer Best Selling Brand at Retailers
3. Exergen TemporalScanner Sponsors Game Time Temperature for NFL and College Bowl Games
4. Exergen Game Time Temperature Contest Helps Football Fans Tackle Cold and Flu Season
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
9. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
10. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
11. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
Post Your Comments:
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)...  In the pharmaceutical industry, companies want to rapidly ... uncover new insights, tactics and strategies that will improve ... --> However, organizations often find it is difficult ... that all rules and regulations are met to ensure ... to efficiently launching market research projects is the conflicting ...
(Date:11/24/2015)... , November 24, 2015 --> ... report "Spine Biologics Market by Product Type (Bone Graft, Bine ... Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and ... global market was valued at $1.90 Billion in 2014 and ... CAGR of 4.4% during the forecast period of 2015 to ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many ... the doctor uses other traditional cutting tools, such as the scalpel and high-speed drill, ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November 12th ... which patients are or are not eligible for bariatric surgery. The article explains that ... are more than 100 pounds overweight, or have a BMI of 35 and over ...
(Date:11/24/2015)... ... 2015 , ... It takes only three to five seconds to make a ... first impression be positive and reflects business values. If a client starts with a ... to return. They will also share their thoughts about a business with others, which ...
(Date:11/24/2015)... ... 2015 , ... Cancer patients, survivors, caregivers, family members and ... taping of the next CURE Connections® video series on Saturday, Dec. ... at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE Connections, ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
Breaking Medicine News(10 mins):